San Diego, California–(Newsfile Corp. – July 7, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with the University of Michigan to perform research related to Tryp’s Psilocybin-for-Neuropsychiatric…

Source

Previous articleMYND Life Sciences Provides Corporate Update
Next articleQ & A with Keeno Ahmed-Jones: Dismantling the Echo Chamber of the Psychedelic Renaissance